Through Pitch & Match, we provide our investors and presenting companies the opportunity to get to know each other before event day, get engaged through presentation, Q&A and arrange immediate follow-up meetings.

Presentation fees: $3000 (Includes presentation fee and one registration for presenter)

Presentation Companies Can:
– Meet pre-vetted decision makers from top Chinese pharma and investment firms
– Know your audience prior to the pitch
– Maximized your company visibility through pre-conference promotion
– Present for 8min with Powerpoint
– Schedule immediate follow-up meetings through on-target partnering

Who Should Apply

  • Biotech
  • Drug development
  • Platform technology
  • Medical device
  • Digital health
  • Synthetic biology
  • Research tools

Opportunities our audience are seeking

  • Equity Investment
  • Licensing
  • Co-Development
  • M&A
  • Joint Venture
  • And more…

Apply Now

Presentation fees: $3000 (Includes presentation fee and one registration for presenter)

Please note: once your company is selected and accepts the offer of a presentation slot, you will be required to pay the fees within 10 business days to secure a time slot. Failure to timely pay fees may result in a delay in scheduling pre-event promotion and other service.


Presenting companies will receive

  • Free consultation on 1-on-1 partnering
  • Receive a list of featured audience and their partnering demand prior to the event day
  • Pre-conference promotion to all conference attendees
  • 8-min PowerPoint presentation during the conference
  • Immediate follow-up meetings through on-target partnering

To present at China Focus@San Francisco please complete the following application form. This information will be used to evaluate your company for a presentation slot. If selected to present, you will receive additional steps to submit payment and secure your presentation slot.
  • Date Format: MM slash DD slash YYYY
If you would like to submit a company deck instead, please email [email protected]

PAST Featured Audiences

Hengrui Pharmaceuticals

Description: A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017 and a market cap of $31 billion.

Recent Deal: Mycovia and Hengrui Medicine have signed an agreement to develop and commercialise the former’s investigational drug, VT-1161 for RVVC

Interests: oncology, autoimmune, metabolic and CV


Description: CSPC was recognized as the top brand for its compliance culture, ethical business and innovation

Recent Deal: Verastem grants CSPC exclusive rights to develop and commercialize the cancer drug Copiktra duvelisib in China.

Interests: Oncology, CV, Autoimmune


Fosun Pharma

Description: Established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform.

Recent Deal: Revance Therapeutics grants Fosun exclusive Chinese rights to RT002.

Interests: oncology, cardiovascular disease, CNS, liver disease, medical device

Salubris Pharmaceuticals

Description: Salubris is a globally integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution.

Recent Deal: Viracta Therapeutics Inc. granted Salubris exclusive rights to develop and sell its virus-related cancer therapy nanatinostat/valganciclovir in the great China.

Interests: Oncology, CV and metabolic diseases

Luye Pharma

Description: Luye Pharma is an international pharmaceutical company with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas.

Recent Deal: Luye Pharma and PharmaMar Sign Licensing Agreement for the Development and Commercialization of Zepsyre® in China.

Interests: Oncology, CNS, CV, diabetes, digestive disease and metabolic diseases

Huadong Medicine

Description: A fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines, with annual revenue of 4.5 billion USD.

Recent Deal: Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other Markets

Interests: Diabetes, Aesthetics, autoimmune disease, digestive disease, CV, oncology, and infectious disease.